高级检索
当前位置: 首页 > 详情页

Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial

文献详情

资源类型:
Pubmed体系:
机构: [1]Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, Beijing, China [2]Department of Oncology, The Affiliated Hospital of Jining Medical College, Jining, China [3]Department of Medical Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China [4]Special Needs Ward, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China [5]Department of Medical Oncology, Nantong Tumour Hospital, Nantong, China [6]Department of Medical Oncology, Northern Jiangsu People’s Hospital, Affiliated Hospital to Yangzhou University, Yangzhou, China [7]Department of Radiotherapy and Chemotherapy, Tangshan People’s Hospital, Tangshan, China [8]Department of Medical Oncology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, China [9]Department of Oncology, Jiangsu Cancer Hospital, Nanjing Medical University, Nanjing, China [10]Department of Medical Oncology, Anhui Provincial Cancer Hospital, University of Science and Technology of China, Hefei, China [11]Department of Oncology, Fujian Provincial Hospital, Fuzhou, China [12]Department of Medical Oncology, Suining Central Hospital, Suining, China [13]Department of Medical Oncology, The Affiliated Hospital of Qingdao University, Qingdao, China [14]Department of Thoracic Surgery Ward 2, Yunnan Cancer Hospital, Kunming, China [15]Department of Medical Oncology, Henan Tumour Hospital, Zhengzhou, China [16]Department of Thoracic Tumour Radiotherapy Ward 2, Jiangxi Cancer Hospital, Nanchang, China [17]Department of Medical Oncology, Inner Mongolia People’s Hospital, Hohhot, China [18]Department of Digestive Oncology Ward 2, Harbin Medical University Cancer Hospital, Harbin, China [19]Department of Medical Oncology, Puyang Oilfield General Hospital, Puyang, China [20]Department of Medical Oncology Three, Handan Central Hospital, Handan, China [21]Department of Oncology, Qilu Hospital of Shandong University, Jinan, China [22]Oncology Department, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China [23]Department of Tumour Chemotherapy, Anhui Provincial Hospital, Hefei, China [24][24] [25]Department of Medical Oncology, Centre François Baclesse, Caen, France [26][26] [27]Department of Gastroenterology and Digestive Oncology, Hôpital Européen Georges Pompidou, Paris, France [28]Medical Science and Strategy Oncology, Innovent Biologics, China [29]Department of Statistics, Innovent Biologics, China [30]Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, China
出处:
ISSN:

摘要:
To evaluate sintilimab versus placebo in combination with chemotherapy (cisplatin plus paclitaxel or cisplatin plus 5-fluorouracil) as first line treatment of unresectable locally advanced, recurrent, or metastatic oesophageal squamous cell carcinoma.Multicentre, randomised, double blind, phase 3 trial.66 sites in China and 13 sites outside of China between 14 December 2018 and 9 April 2021.659 adults (aged ≥18 years) with advanced or metastatic oesophageal squamous cell carcinoma who had not received systemic treatment.Participants were randomised 1:1 to receive sintilimab or placebo (3 mg/kg in patients weighing <60 kg or 200 mg in patients weighing ≥60 kg) in combination with cisplatin 75 mg/m2 plus paclitaxel 175 mg/m2 every three weeks. The trial was amended to allow investigators to choose the chemotherapy regimen: cisplatin plus paclitaxel or cisplatin plus 5-fluorouracil (800 mg/m2 continuous infusion on days 1-5).Overall survival in all patients and in patients with combined positive scores of ≥10 for expression of programmed cell death ligand 1.659 patients were randomly assigned to sintilimab (n=327) or placebo (n=332) with chemotherapy. 616 of 659 patients (93%) received sintilimab or placebo in combination with cisplatin plus paclitaxel and 43 of 659 patients (7%) received sintilimab or placebo in combination with cisplatin plus 5-fluorouracil. At the interim analysis, sintilimab with chemotherapy showed better overall survival compared with placebo and chemotherapy in all patients (median 16.7 v 12.5 months, hazard ratio 0.63, 95% confidence interval 0.51 to 0.78, P<0.001) and in patients with combined positive scores of ≥10 (17.2 v 13.6 months, 0.64, 0.48 to 0.85, P=0.002). Sintilimab and chemotherapy significantly improved progression free survival compared with placebo and chemotherapy in all patients (7.2 v 5.7 months, 0.56, 0.46 to 0.68, P<0.001) and in patients with combined positive scores of ≥10 (8.3 v 6.4 months, 0.58, 0.45 to 0.75, P<0.001). Adverse events related to treatment occurred in 321 of 327 patients (98%) in the sintilimab-chemotherapy group versus 326 of 332 (98%) patients in the placebo-chemotherapy group. Rates of adverse events related to treatment, grade ≥3, were 60% (196/327) and 55% (181/332) in the sintilimab-chemotherapy and placebo-chemotherapy groups, respectively.Compared with placebo, sintilimab in combination with cisplatin plus paclitaxel showed significant benefits in overall survival and progression free survival as first line treatment in patients with advanced or metastatic oesophageal squamous cell carcinoma. Similar benefits of sintilimab with cisplatin plus 5-fluorouracil seem promising.ClinicalTrials.gov NCT03748134.© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

语种:
PubmedID:
第一作者:
第一作者机构: [1]Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, Beijing, China
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:82494 今日访问量:0 总访问量:681 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 云南省第一人民医院 技术支持:重庆聚合科技有限公司 地址:云南省昆明市西山区金碧路157号